Adaptation of Arabic Translations of Cancer Patient-Reported Outcomes Assessment Tools: An Unmet Need
Loay
Kassem
Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Samy
Alsirafy
Palliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
text
article
2016
eng
Research in Oncology
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
2357-0687
12
v.
2
no.
2016
31
32
https://resoncol.journals.ekb.eg/article_2536_f5a7e098e8e1a39cb34f9396047c9c69.pdf
dx.doi.org/10.21608/resoncol.2017.697.1017
Outcome of Patients with Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases: Egyptian Experience
Salah
Elmesidy
Department of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Hussam
Zawam
Department of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Asmaa
Hassan
Department of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Mohamed
Abol-Kasem
Department of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Radwa
Fawzy
Department of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Mahmoud
Abdelsalam
Department of Clinical Oncology, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
text
article
2016
eng
Background: Lung cancer remains the most common primary tumor responsible for brain metastases making up to 40% to 50% of cases. Brain metastases from NSCLC is associated with poor prognosis. Aim: The aim of this study is to analyze the risk factors and treatment outcome of patients with NSCLC who developed brain metastases; and to identify which subgroup of these patients is associated with better survival outcome. Methods: We analyzed all patients with NSCLC presented to Kasralainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK) during the period between January 2006 and December 2012. Seven hundred and fourteen patients were found, from which 132 had clinical evidence of brain metastases. Results: The median time to development of brain metastases (TTBM) was 6 months. Factors associated with longer TTBM were good PS (1-2) (P=0.004), early stages at presentation (stage I&II) (P<0.0001) and administration of chemotherapy (P<0.0001). Median overall survival from the time of development of brain metastases was 5 months. Factors associated with longer OS were; good PS (1&2) at development of brain metastases (P<0.0001), controlled lung primary (P<0.0001), absence of extracranial metastases (P=0.019), the use of chemotherapy after development of brain metastases (P<0.0001) and whole brain irradiation (P=0.001). Controlled lung primary and administration of chemotherapy were independent prognostic factors associated with higher OS (P= 0.006 and 0.02 respectively). Conclusion: After development of brain metastases; patients with good PS(1-2), controlled lung primary and absence of extracranial metastases are associated with better outcome than other cases.
Research in Oncology
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
2357-0687
12
v.
2
no.
2016
33
39
https://resoncol.journals.ekb.eg/article_2537_696323f8a97bbcd3ae68dce38faeea96.pdf
dx.doi.org/10.21608/resoncol.2017.615.1014
A Prospective Study of Adjuvant Radiotherapy Concomitant with Cisplatin Followed by Paclitaxel-Carboplatin in High Risk Early Stage Endometrial Cancer
Tarek
Kamel
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
author
Walid
Bayoumy
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
author
Mohamed
Al-Kady
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
author
Mohamed
Mustafa
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
author
Caroline
El-Maraghi
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
author
text
article
2016
eng
Abstract: Purpose: To study the efficacy and toxicity of adjuvant radiotherapy concomitant with cisplatin followed by paclitaxel, carboplatin in high risk early stage endometrial cancer. Patient and methods: Patients with higher risk endometrial cancer defined in this study as those having > 50% myometrial invasion or grade 3 or lymphovascular invasion positive or those stage II, IIIA, or finally those with clear cell or papillary serous histology whatever the stage were enrolled post total abdominal hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy. Patients received adjuvant pelvic external beam (RTH) (46.8-50.4 Gy) concomitant with cisplatin (50 mg/m2) every 21 days followed by 4 cycles of paclitaxel 175 mg/m2 carboplatin (AUC5) every 21 days. Primary end point was disease free survival and the secondary end point were tolerability and toxicity. Results 21 patients from clinical Oncology Department, Ain Shams University from June 2013-March 2016 were enrolled. The median follow up time was 21 months (range from 9—33 months). 19 patients (90.41%) completed the RTH and the 4 cycles of adjuvant CTH. Overall grade 3-4 hematological toxicity was 23.8%, it was mainly neutropenia. Grade 3-4 non hematological toxicity was seen in 3 patients (14.28%), 2 patients had grade 3 neuropathy and a third patient experienced grade 3 diarrhea with the chemotherapy. Disease recurrence was registered in 3/21 patients (14.28%). The 1 and 2 years DFS were 93.8% and 73.8% respectively. Conclusion: Adjuvant sequential RTH followed by paclitaxel, carboplatin is well tolerated and feasible regimen in patients with higher risk EC.
Research in Oncology
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
2357-0687
12
v.
2
no.
2016
40
46
https://resoncol.journals.ekb.eg/article_2540_eeb0bfc1480290acfcc316e0de17ba26.pdf
dx.doi.org/10.21608/resoncol.2017.234.1010
Effect of Chemotherapy on the Nutritional Status of Egyptian Patients with Breast Cancer
Soha
Talima
Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Lamia
Nabil
Medical Surgical Department, Faculty of Nursing, Cairo University, Cairo, Egypt
author
Mahmoud
El-Meghawry
Medical Surgical Department, Faculty of Nursing, Cairo University, Cairo, Egypt
author
text
article
2016
eng
Background: Chemotherapy and chemotherapy-related symptoms may greatly affect the nutritional status of the patient and reduces the quality of life. Aim of the study: Assessment of the effect of chemotherapy on the nutritional status of breast cancer patients. Methods: In this prospective observational study, we assessed the nutritional status of 60 breast cancer patients receiving chemotherapy by anthropometric measurements including body weight (BW), body mass index (BMI), triceps skin fold (TSF), and mid arm muscle circumference (MAMC). Symptoms related to chemotherapy wereassessed with a yes/no questionnaire. Results: Forty three patients (71%) experienced weight loss during the course of treatment. Compared to baseline assessment before starting chemotherapy, there was a significant reduction in the average of all parameters at the end of chemotherapy. Body weight decreased from 78.97 (±9.6) kg to 73.65 (±14.1) kg, BMI from 30.15 (±3.2) kg/m2 to 28.01 (±4.8) kg/m2, TSF from 4.23 (±0.5) cm to 3.97 (±0.68) cm and MAMC from 36.31 (4.02) cm to 34.61 (±5.04) cm (p < 0.001 for all). Significant reduction in BMI observed in patients who experienced alteration in taste especially those with taste alteration for > 1 week (p < 0.001). Similarly, BMI reduction was significantly associated with loss of appetite and its duration (p < 0.001). Conclusion: During chemotherapy, breast cancer patients are prone to lose weight particularly, those patients who experience taste alteration and appetite-loss for longer duration
Research in Oncology
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
2357-0687
12
v.
2
no.
2016
47
53
https://resoncol.journals.ekb.eg/article_2570_68b682e7310764f1f76d11685e1a7649.pdf
dx.doi.org/10.21608/resoncol.2017.656.1016
Effect of Body Mass Index on Survival in Patients with Epithelial Ovarian Cancer
Suzy
Gohar
Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Shibin Elkom, Egypt
author
Ashraf
Abdel-Ghany
Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Shibin Elkom, Egypt
author
Shaimaa
Soliman
Department of Public Health and Community Medicine, Faculty of Medicine, Menoufia University, Shibin Elkom, Egypt
author
text
article
2016
eng
Introduction: Higher body mass index (BMI) is an independent and well-established prognostic factor in hormonerelatedcancers, such as breast and endometrial cancer. As a hormone-dependent cancer, ovarian cancer, however, has been linked inconsistently to obesity. Aim: This work aimed to assess the association between BMI and ovarian cancer survival.Methods: This retrospective study included 66 patients who were treated for epithelial ovarian cancer from January 2011to April 2014. Clinical and epidemiological characteristics of patients were collected. Time to progression and overall survival were calculated. BMI was calculated using the formula weight in kilograms divided by the square of the height in meters, and categorized according to World Health Organization classification.Results: BMI indicated underweight in 3 patients (4.5%), healthy weight range in11 (16.7%), pre-obesity in 17 (25.8%),obesity class I in 13 (19.7%), obesity class II in 8 (12.1%) and obesity class III in 14 (21.2%). BMI did not associate significantly with disease stage (p=0.54), pathology (p=0.82), initial CA-125 level (p=0.61), platinum sensitivity(p=0.27), time to progression (p=0.58) or overall survival (p=0.87).Conclusion: Our results suggest prevalence of obesity (relatively high) among Egyptian patients with epithelial ovarian cancer. Noteworthy, BMI had no significant association with disease stage, platinum sensitivity, time-to-progression or overall survival in the studied group.
Research in Oncology
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
2357-0687
12
v.
2
no.
2016
54
59
https://resoncol.journals.ekb.eg/article_2577_03bb88f2a22821fadfeadfd867cef450.pdf
dx.doi.org/10.21608/resoncol.2017.223.1007
Awareness of Diagnosis in Patients with Cancer: A Study from Egypt
Ahmad
Hammad
Palliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Dina
Farag
Palliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Mostafa
El-Haddad
Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Rasha
Haggag
Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
author
Omar
Zaki
Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Noha
Ibrahim
Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
Samy
Alsirafy
Palliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
author
text
article
2016
eng
Background: One of the barriers to cancer care is the inadequate communication with patients and their families. InEgypt, it is believed that culture is against the honest disclosure of cancer diagnosis. So, the majority of cancer patientsare usually unaware of their diagnosis.Aim: To study cancer diagnosis awareness among a group of Egyptian patients and the factors contributing to their unawareness. Methods: The study included 119 cancer patients from two cancer centers; one in Cairo and the other in Sharkia. Patients were asked about their illness and who answered as having cancer/tumor” or mentioned the name of cancer considered aware. Results: The majority of our patients (100/119, 84%) were aware of their cancer diagnosis. Their answer was “cancer” in 31%, “tumor” in 60% and the name of cancer in 9%. While, a nority (19 /119, 16%), were unaware of their cancer diagnosis. They were more likely to be less educated, older in age, males, unmarried, and from Sharkia. None of the studied variables associated significantly with awareness. Conclusions: The results of this study suggest that most cancer patients in Egypt are aware of their diagnosis. This may be due to a change in the Egyptian cultural attitude towards truth telling and a shift in the approach of care from paternalistic to patient-centred.
Research in Oncology
Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
2357-0687
12
v.
2
no.
2016
60
63
https://resoncol.journals.ekb.eg/article_2585_984da33d1f33c927ac2e205efc0155cf.pdf
dx.doi.org/10.21608/resoncol.2016.332.1011